Summary of efficacy end points in the efficacy-evaluable set
| . | Efficacy-evaluable set (N = 257) . |
|---|---|
| ORR,∗ n (%, 95% CI†) | 187 (73%, 66.9-78.1) |
| CR rate,∗ n (%, 95% CI†) | 136 (53%, 46.6-59.2) |
| Median time to first response (range),∗ mo | 0.95 (0.7-8.9) |
| Median time to first CR (range),∗ mo | 0.95 (0.8-12.5) |
| Median DOR (95% CI‡,),∗ mo | 23.1 (8.6-NR) |
| Median follow-up (95% CI§), mo | 23.0 (22.8-23.1) |
| Probability of continued response at 24 mo (95% CI‡), % | 49.5 (41.4-57.0) |
| Median DOR∗,in patients who achieved CR (95% CI‡ ), mo | 26.1 (23.1-NR) |
| Median follow-up (95% CI§), mo | 23.1 (23.0-23.2) |
| Probability of continued response at 24 mo (95% CI‡), % | 58.5 (49.2-66.7) |
| Median PFS (95% CI‡,),∗ mo | 6.8 (3.3-12.7) |
| Median follow-up (95% CI§), mo | 23.9 (23.7-24.0) |
| Probability of PFS at 24 mo (95% CI‡), % | 40.6 (34.0-47.2) |
| Median OS (95% CI‡ ), mo | 27.3 (16.2-45.6) |
| Median follow-up (95% CI§), mo | 29.3 (26.2-30.4) |
| Probability of OS at 24 mo (95% CI‡), % | 50.5 (44.1-56.5) |
| . | Efficacy-evaluable set (N = 257) . |
|---|---|
| ORR,∗ n (%, 95% CI†) | 187 (73%, 66.9-78.1) |
| CR rate,∗ n (%, 95% CI†) | 136 (53%, 46.6-59.2) |
| Median time to first response (range),∗ mo | 0.95 (0.7-8.9) |
| Median time to first CR (range),∗ mo | 0.95 (0.8-12.5) |
| Median DOR (95% CI‡,),∗ mo | 23.1 (8.6-NR) |
| Median follow-up (95% CI§), mo | 23.0 (22.8-23.1) |
| Probability of continued response at 24 mo (95% CI‡), % | 49.5 (41.4-57.0) |
| Median DOR∗,in patients who achieved CR (95% CI‡ ), mo | 26.1 (23.1-NR) |
| Median follow-up (95% CI§), mo | 23.1 (23.0-23.2) |
| Probability of continued response at 24 mo (95% CI‡), % | 58.5 (49.2-66.7) |
| Median PFS (95% CI‡,),∗ mo | 6.8 (3.3-12.7) |
| Median follow-up (95% CI§), mo | 23.9 (23.7-24.0) |
| Probability of PFS at 24 mo (95% CI‡), % | 40.6 (34.0-47.2) |
| Median OS (95% CI‡ ), mo | 27.3 (16.2-45.6) |
| Median follow-up (95% CI§), mo | 29.3 (26.2-30.4) |
| Probability of OS at 24 mo (95% CI‡), % | 50.5 (44.1-56.5) |